Mechanical valves are typically preferred for younger patients as they have a longer lifespan compared to other types of prosthetic heart valves.

Prosthetic Heart Valves: Options for Replacement

Prosthetic heart valves are commonly used to replace damaged aortic and mitral valves. There are two main options for replacement: biological (bioprosthetic) or mechanical. Biological valves are usually sourced from bovine or porcine origins and are commonly used in older patients. However, they have a major disadvantage of structural deterioration and calcification over time. On the other hand, mechanical valves have a low failure rate but require long-term anticoagulation due to the increased risk of thrombosis. Warfarin is still the preferred anticoagulant for patients with mechanical heart valves, and the target INR varies depending on the valve type. Aspirin is only given in addition if there is an additional indication, such as ischaemic heart disease. Following the 2008 NICE guidelines, antibiotics are no longer recommended for common procedures such as dental work for prophylaxis of endocarditis.

When treating heart failure patients, it is recommended to initiate therapy with either an angiotensin-converting enzyme (ACE) inhibitor or a beta-blocker licensed for heart failure treatment, but not both simultaneously. If the patient exhibits signs of fluid overload or has diabetes mellitus, an ACE inhibitor like ramipril is preferred. On the other hand, if the patient has angina, a beta-blocker such as bisoprolol, carvedilol, or nebivolol is preferred.

Drug Management for Chronic Heart Failure: NICE Guidelines

Chronic heart failure is a serious condition that requires proper management to improve patient outcomes. In 2018, the National Institute for Health and Care Excellence (NICE) updated their guidelines on drug management for chronic heart failure. The guidelines recommend first-line therapy with both an ACE-inhibitor and a beta-blocker, with clinical judgement used to determine which one to start first. Second-line therapy involves the use of aldosterone antagonists, which should be monitored for hyperkalaemia. SGLT-2 inhibitors are also increasingly being used to manage heart failure with a reduced ejection fraction. Third-line therapy should be initiated by a specialist and may include ivabradine, sacubitril-valsartan, hydralazine in combination with nitrate, digoxin, or cardiac resynchronisation therapy. Other treatments such as annual influenza and one-off pneumococcal vaccines are also recommended.

Overall, the NICE guidelines provide a comprehensive approach to drug management for chronic heart failure. It is important to note that loop diuretics have not been shown to reduce mortality in the long-term, and that ACE-inhibitors and beta-blockers have no effect on mortality in heart failure with preserved ejection fraction. Healthcare professionals should carefully consider the patient’s individual needs and circumstances when determining the appropriate drug therapy for chronic heart failure.

Anteroseptal changes in V1-V4 indicate involvement of the left anterior descending artery.
Inferior changes in II, III, and aVF suggest the right coronary artery is affected.
Anterolateral changes in V1-6, I, and aVL indicate the proximal left anterior descending artery is involved.
Lateral changes in I, aVL, and possibly V5-6 suggest the left circumflex artery is affected.
Posterior changes in V1-3 may indicate a posterior infarction, which is confirmed by ST elevation and Q waves in posterior leads (V7-9). This type of infarction is usually caused by the left circumflex artery, but can also be caused by the right coronary artery.
Reciprocal changes of STEMI are typically seen as horizontal ST depression, tall and broad R waves, upright T waves, and a dominant R wave in V2. It is important to note that a new left bundle branch block (LBBB) may indicate acute coronary syndrome.

Overall, understanding the correlation between ECG changes and coronary artery territories is crucial in diagnosing acute coronary syndrome. By identifying the specific changes in the ECG, medical professionals can determine which artery is affected and provide appropriate treatment. Additionally, recognizing the reciprocal changes of STEMI and the significance of a new LBBB can aid in making an accurate diagnosis.

Comparing Beta Blockers for Heart Failure: Efficacy and Evidence

Beta blockers are a class of medications commonly used in the treatment of heart failure. Among them, bisoprolol and carvedilol have the strongest evidence of efficacy in reducing mortality rates in heart failure patients, according to data from the CIBIS and CASA-2 trials. Atenolol, although cardioselective, has less evidence to support its use in heart failure. Labetalol is primarily used for hypertension in pregnancy, while propranolol has the most evidence of benefit after a myocardial infarction but is not always preferred due to its twice-daily dosing. Sotalol, a first-generation beta blocker, is not cardioselective and is not recommended for heart failure. Overall, the choice of beta blocker for heart failure should be based on the available evidence and individual patient factors.

For a patient with poorly controlled hypertension who is already taking an ACE inhibitor, the addition of a calcium channel blocker or a thiazide-like diuretic is recommended. In individuals under the age of 55 and of Caucasian ethnicity, the first-line treatment for hypertension is an ACE inhibitor such as ramipril. If the blood pressure remains elevated despite maximum dose of ramipril, a second medication should be added. A calcium channel blocker or thiazide-like diuretic is the preferred choice for second-line therapy in this scenario.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Managing Cardiac Arrest: Correct and Incorrect Approaches

When dealing with a patient in cardiac arrest, it is crucial to follow the correct management protocol. In the case of a patient in asystole, CPR 30:2 (compressions: ventilations) should be initiated, along with 1 mg of adrenaline 10 ml of 1:10 000 IV every other cycle of CPR. Direct current (DC) shock is not indicated for asystole. Adrenaline 1:1000 IM is not appropriate for cardiac arrest situations, as it is used in anaphylaxis. External pacing is unlikely to be successful in the absence of P-wave asystole. Atropine is indicated in severe bradycardia, not asystole. It is essential to follow the correct approach to manage cardiac arrest effectively.

Medications for Heart Failure: Benefits and Guidelines

Heart failure is a serious condition that requires proper management through medications. Among the drugs commonly used are bisoprolol, bendroflumethiazide, clopidogrel, spironolactone, and diltiazem.

Bisoprolol and an angiotensin-converting enzyme (ACE) inhibitor are recommended for all heart failure patients as they have been shown to reduce mortality. Bendroflumethiazide and loop diuretics like furosemide can help alleviate symptoms but do not have a mortality benefit. Clopidogrel, on the other hand, is not indicated for heart failure but is used for vascular diseases like NSTEMI and stroke.

Spironolactone is recommended for patients who remain symptomatic despite treatment with an ACE inhibitor and a b blocker. It is also beneficial for those with left ventricular systolic dysfunction (LVSD) after a myocardial infarction (MI). However, diltiazem should be avoided in heart failure patients.

According to NICE guidelines, b blockers and ACE inhibitors should be given to all LVSD patients unless contraindicated. Spironolactone can be added if symptoms persist. Proper medication management is crucial in improving outcomes for heart failure patients.

The National Institute for Health and Care Excellence recommends using a β blocker or calcium channel blocker as the first-line treatment for angina, along with a statin. If a patient is intolerant to β blockers or not responding to a CCB alone, a long-acting nitrate can be added. An ACE inhibitor is not indicated for angina treatment. Beta blockers and CCBs can be used together if one alone does not control symptoms, but caution is needed to avoid conduction problems. Long-acting nitrates should only be used in isolation if CCB or β blocker use is contraindicated. Aspirin is recommended for secondary prevention, and short-acting nitrates can be used for symptom relief. The 4S study showed that statins significantly reduce the risk of MI in patients with angina and high cholesterol levels.

During CPR, thrombolytic drugs should be considered if a pulmonary embolism (PE) is suspected. Alteplase is a suitable option for advanced life support (ALS) in such cases. This is particularly relevant for patients who present with symptoms suggestive of a PE and have a medical history of previous pulmonary emboli. Thrombolysis can be a life-saving intervention for these patients.

Adenosine is not appropriate for this situation as it is a class 5 antiarrhythmic used mainly for supraventricular tachycardia. Apixaban is an anticoagulant that is useful for long-term treatment and prevention of pulmonary emboli, but it is not suitable for immediate use in a hemodynamically unstable patient requiring advanced life support. Clopidogrel is an antiplatelet medication that is used in peripheral arterial disease and acute coronary syndrome, but it has no role in the acute treatment of a life-threatening pulmonary embolism.

The 2015 Resus Council guidelines for adult advanced life support outline the steps to be taken when dealing with patients with shockable and non-shockable rhythms. For both types of patients, chest compressions are a crucial part of the process, with a ratio of 30 compressions to 2 ventilations. Defibrillation is recommended for shockable rhythms, with a single shock for VF/pulseless VT followed by 2 minutes of CPR. Adrenaline and amiodarone are the drugs of choice for non-shockable rhythms, with adrenaline given as soon as possible and amiodarone administered after 3 shocks for VF/pulseless VT. Thrombolytic drugs should be considered if a pulmonary embolus is suspected. Atropine is no longer recommended for routine use in asystole or PEA. Oxygen should be titrated to achieve saturations of 94-98% following successful resuscitation. The Hs and Ts should be considered as potential reversible causes of cardiac arrest.

If the Wells score for a suspected deep vein thrombosis (DVT) is 2 or higher, a proximal leg vein ultrasound scan should be arranged within 4 hours. In this case, the patient’s Wells score is 2 due to recent major surgery within 12 weeks and a calf swelling at least 3 cm larger than the asymptomatic side. It is important to note that a CT angiogram of the leg is not appropriate for diagnosing DVT, and ultrasound is the preferred imaging modality. A CT pulmonary angiogram would only be necessary if the patient had symptoms suggestive of pulmonary embolism. A chest X-ray is not relevant in this scenario. If ultrasound is not possible within 4 hours, a D-dimer test could be performed and interim therapeutic anticoagulation given, but the initial choice is to perform an ultrasound scan as soon as possible.

NICE updated their guidelines on the investigation and management of venous thromboembolism (VTE) in 2020. The use of direct oral anticoagulants (DOACs) is recommended as first-line treatment for most people with VTE, including as interim anticoagulants before a definite diagnosis is made. Routine cancer screening is no longer recommended following a VTE diagnosis. The cornerstone of VTE management is anticoagulant therapy, with DOACs being the preferred choice. All patients should have anticoagulation for at least 3 months, with the length of anticoagulation being determined by whether the VTE was provoked or unprovoked.